AU2018301412B2 - Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof - Google Patents

Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof

Info

Publication number
AU2018301412B2
AU2018301412B2 AU2018301412A AU2018301412A AU2018301412B2 AU 2018301412 B2 AU2018301412 B2 AU 2018301412B2 AU 2018301412 A AU2018301412 A AU 2018301412A AU 2018301412 A AU2018301412 A AU 2018301412A AU 2018301412 B2 AU2018301412 B2 AU 2018301412B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
fusion protein
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018301412A
Other languages
English (en)
Other versions
AU2018301412A1 (en
AU2018301412A9 (en
Inventor
Julian Chandler
Nimish GERA
Siddharth JINDAL
Bridget Puffer
Douglas L. Sheridan
Paul P. Tamburini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2018301412A1 publication Critical patent/AU2018301412A1/en
Priority to AU2025200303A priority Critical patent/AU2025200303A1/en
Priority to AU2025200313A priority patent/AU2025200313A1/en
Application granted granted Critical
Publication of AU2018301412B2 publication Critical patent/AU2018301412B2/en
Publication of AU2018301412A9 publication Critical patent/AU2018301412A9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2018301412A 2017-07-11 2018-07-11 Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof Active AU2018301412B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2025200303A AU2025200303A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
AU2025200313A AU2025200313A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531215P 2017-07-11 2017-07-11
US62/531,215 2017-07-11
PCT/US2018/041661 WO2019014360A1 (en) 2017-07-11 2018-07-11 POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2025200303A Division AU2025200303A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
AU2025200313A Division AU2025200313A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Publications (3)

Publication Number Publication Date
AU2018301412A1 AU2018301412A1 (en) 2020-01-30
AU2018301412B2 true AU2018301412B2 (en) 2025-08-07
AU2018301412A9 AU2018301412A9 (en) 2025-08-07

Family

ID=63036501

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018301412A Active AU2018301412B2 (en) 2017-07-11 2018-07-11 Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
AU2025200303A Pending AU2025200303A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
AU2025200313A Pending AU2025200313A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2025200303A Pending AU2025200303A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
AU2025200313A Pending AU2025200313A1 (en) 2017-07-11 2025-01-16 Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Country Status (12)

Country Link
US (3) US11498960B2 (enExample)
EP (1) EP3625265A1 (enExample)
JP (3) JP7684803B2 (enExample)
KR (3) KR20250099285A (enExample)
CN (3) CN117327188A (enExample)
AU (3) AU2018301412B2 (enExample)
BR (1) BR112019028269A2 (enExample)
CA (1) CA3067247A1 (enExample)
CO (1) CO2020000369A2 (enExample)
IL (3) IL307197B2 (enExample)
MX (2) MX2024005945A (enExample)
WO (1) WO2019014360A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307197B2 (en) 2017-07-11 2026-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
WO2020092546A1 (en) * 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
AU2020257185A1 (en) * 2019-04-16 2021-12-16 University Of Washington Amantadine binding protein
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
EP4052710A4 (en) 2019-12-26 2024-02-28 Eisai R&D Management Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING DOUBLE-STRANDED RIBONUCLEIC ACID INHIBITING THE EXPRESSION OF COMPLEMENT C5
JP7343618B2 (ja) 2020-01-17 2023-09-12 オリンパス株式会社 発光装置、および駆動装置
US20230416344A1 (en) 2020-04-16 2023-12-28 Alexion Pharmaceuticals, Inc. Methods for treating a complement mediated disorder caused by viruses
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
CN116472065A (zh) * 2020-10-05 2023-07-21 阿雷克森制药公司 治疗皮肌炎的方法
KR20250030978A (ko) * 2022-06-03 2025-03-05 알렉시온 파마슈티칼스, 인코포레이티드 중증 근무력증의 치료를 위한 융합 폴리펩티드의 투여량 및 투여
JP2025531719A (ja) * 2022-08-31 2025-09-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 鎌状赤血球症の治療のための融合ポリペプチドの投薬及び投与
CN116731149B (zh) * 2023-06-07 2024-02-27 华中农业大学 草鱼补体活化分子碳末端肽C5a-CP及应用
CN119241699B (zh) * 2024-09-24 2025-11-28 广州康盛生物科技股份有限公司 一种抗人补体c5的单域抗体及其应用
CN121518561B (zh) * 2025-12-24 2026-06-05 北京林业大学 一种PagRAP2.3蛋白点突变及其在植物愈伤再生中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015608A1 (en) * 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
WO2010151526A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1355919B1 (en) * 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
CN100379762C (zh) * 2003-12-08 2008-04-09 中国人民解放军军事医学科学院生物工程研究所 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
AU2012254935B2 (en) * 2004-02-12 2014-05-29 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN100368022C (zh) 2005-09-20 2008-02-13 中国人民解放军第二军医大学 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法
WO2007045465A1 (en) * 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
JP2009055838A (ja) * 2007-08-31 2009-03-19 Nipro Corp 融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物
DK2262831T3 (en) 2008-03-03 2015-04-27 Novelmed Therapeutics Inc ANTI-Properdin ANTIBODIES
WO2011034660A1 (en) 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP2531523A1 (en) * 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
EP2545075B1 (en) 2010-03-10 2020-07-01 NovelMed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
BR112013000452A2 (pt) 2010-07-09 2020-02-11 Affibody Ab Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
AU2012234284B2 (en) * 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
JP6293659B2 (ja) 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
WO2013102123A2 (en) 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
KR102149028B1 (ko) 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
US9926366B2 (en) 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
US9982022B2 (en) 2013-08-28 2018-05-29 Affibody Ab Binding polypeptides having a mutated scaffold
WO2015028558A1 (en) 2013-08-28 2015-03-05 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement c5
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
KR20260069620A (ko) 2017-01-30 2026-05-15 알렉시온 파마슈티칼스, 인코포레이티드 1가 항-프로페르딘 항체 및 항체 단편
IL307197B2 (en) 2017-07-11 2026-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015608A1 (en) * 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
WO2010151526A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAARTEN VAN ROY ET AL: "The preclinical pharmacology of the high affinity anti-IL-6R Nanobody? ALX-0061 supports its clinical development in rheumatoid arthritis", ARTHRITIS RESEARCH & THERAPY, vol. 17, no. 1, 1 January 2015, pages 1-16 *
ROTHER, R. ET AL., "Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria", NAT. BIOTECHNOL., vol. 25, 2007, pages 1256 - 64 *

Also Published As

Publication number Publication date
CN117327188A (zh) 2024-01-02
CN111201246B (zh) 2023-10-27
IL307197B1 (en) 2025-11-01
BR112019028269A2 (pt) 2020-07-14
US12221473B2 (en) 2025-02-11
EP3625265A1 (en) 2020-03-25
IL307197B2 (en) 2026-03-01
WO2019014360A1 (en) 2019-01-17
US11498960B2 (en) 2022-11-15
US20200399351A1 (en) 2020-12-24
AU2018301412A1 (en) 2020-01-30
US20230235033A1 (en) 2023-07-27
AU2025200303A1 (en) 2025-02-13
RU2020102910A (ru) 2021-08-11
IL307197A (en) 2023-11-01
CO2020000369A2 (es) 2020-01-31
KR20250099285A (ko) 2025-07-01
KR20250068795A (ko) 2025-05-16
JP2020532285A (ja) 2020-11-12
WO2019014360A8 (en) 2019-02-21
MX2024005945A (es) 2024-06-11
RU2020102910A3 (enExample) 2021-12-02
KR20200026264A (ko) 2020-03-10
CN117327187A (zh) 2024-01-02
IL271920B2 (en) 2024-03-01
AU2025200313A1 (en) 2025-02-13
IL271920B1 (en) 2023-11-01
JP2025118590A (ja) 2025-08-13
US20250163138A1 (en) 2025-05-22
AU2018301412A9 (en) 2025-08-07
MX2024005946A (es) 2024-06-11
IL324119A (en) 2025-12-01
CN111201246A (zh) 2020-05-26
KR102806328B1 (ko) 2025-05-14
JP7684803B2 (ja) 2025-05-28
IL271920A (en) 2020-02-27
CA3067247A1 (en) 2019-01-17
JP2023120208A (ja) 2023-08-29

Similar Documents

Publication Publication Date Title
US12221473B2 (en) Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
JP2026053563A (ja) 補体関連疾患のための融合タンパク質構築物
JP7101684B2 (ja) 一価の抗プロペルジン抗体および抗体断片
TWI598361B (zh) Ｃｘ３ｃｒ１－結合多肽
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
US20140286957A1 (en) ANTIBODIES TO CD1d
TWI801425B (zh) Il-5 抗體、其抗原結合片段及醫藥用途
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
TW202409074A (zh) 鬆弛素或類似物的融合蛋白及其醫藥用途
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
HK40106013A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
HK40106012A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
HK40027205B (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
WO2024108529A1 (en) Properdin binding protein and use thereof
HK40027205A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
BR122025022103A2 (pt) Proteína de fusão, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira isolada, polipeptídeo manipulado, e método de preparação da proteína de fusão
KR20250112858A (ko) 프로퍼딘 결합 단백질 및 이의 용도
HK40127090A (en) Epidermal growth factor receptor variant iii antibodies
WO2026008055A1 (zh) 抗kit抗体及其医药用途
WO2025260123A1 (en) Anti-c2 antibodies and uses thereof

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)